PRESS RELEASES Clear Filters October 16, 2025 Gain Therapeutics to Attend the 2025 Maxim Growth Summit Read More October 9, 2025 Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease Read More October 6, 2025 Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders® Read More September 23, 2025 Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 Read More September 18, 2025 Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease Read More September 4, 2025 Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation Read More View More IN THE NEWS Clear Filters October 9, 2025 In the clinic for Oct. 9, 2025 https://www.bioworld.com/articles/724982-in-the-clinic-for-oct-9-2025 Read More October 9, 2025 Allosteric small molecule therapies in PD, with Gene Mack https://pharmaphorum.com/rd/allosteric-small-molecule-therapies-pd-gene-mack Read More October 8, 2025 Early data suggest GT-02287 slows Parkinson’s disease https://www.ddw-online.com/early-data-suggest-gt-02287-slows-parkinsons-disease-37433-202510/ Read More October 8, 2025 New Parkinson’s Drug GT-02287 Shows Promising Phase 1b Data https://www.clinicaltrialvanguard.com/news/new-parkinsons-drug-gt-02287-shows-promising-phase-1b-data/ Read More October 6, 2025 Targeting Parkinson Disease “Pathway Abnormalities” With GT-02287: Jonas Hannestad, MD, PhD https://www.neurologylive.com/view/targeting-parkinson-pathway-abnormalities-gt-02287-jonas-hannestad Read More October 5, 2025 Jonas Hannestad, MD, PhD: Phase 1b Interim Data on GT-02287 in Parkinson Disease https://www.neurologylive.com/view/jonas-hannestad-phase-1b-data-gt-02287-parkinson-disease Read More View More EVENTS Clear Filters October 13, 2025 Parkinson’s Disease KOL Event: Biomarkers, Clinical Endpoints, and the Path to Disease Modification Read More View More
